In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease

BACKGROUND: Liver disease (LD) prolongs mirtazapine half‐life in humans, but it is unknown if this occurs in cats with LD and healthy cats. HYPOTHESIS/OBJECTIVES: To determine pharmacokinetics of administered orally mirtazapine in vivo and in vitro (liver microsomes) in cats with LD and healthy cats...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzpatrick, Rikki L., Quimby, Jessica M., Benson, Kellyi K., Ramirez, Dominique, Sieberg, Liberty G., Wittenburg, Luke A., Gustafson, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272035/
https://www.ncbi.nlm.nih.gov/pubmed/30307637
http://dx.doi.org/10.1111/jvim.15237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272035/
https://www.ncbi.nlm.nih.gov/pubmed/30307637
http://dx.doi.org/10.1111/jvim.15237

Ejemplares similares